Payment overview · 2025
General Payments
$169.16
7 reported records · 4 companies
Healthcare provider profile · identity verified
Renata Z. Ukowska, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BROOKLYN, NY · NPI 1467698563
Verified facts
What the public records show
CMS Open Payments records show Renata Z. Ukowska, MD received $169.16 in general payments during 2025 across 7 reported records.
AstraZeneca Pharmaceuticals LP accounted for 45.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $76.79 | 45.4% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $39.21 | 23.2% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $31.81 | 18.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $21.35 | 12.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $169.16 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $49.57 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $31.81 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $27.22 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $21.35 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $20.21 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $19.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 100 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 33 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
33 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
100 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 377 | 116 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 363 | 119 |
| Losartan Potassium | Losartan Potassium | 361 | 102 |
| Metoprolol Succinate | Metoprolol Succinate | 356 | 124 |
| Levothyroxine Sodium | Levothyroxine Sodium | 329 | 85 |
| Amlodipine Besylate | Amlodipine Besylate | 284 | 94 |
| Metformin Hcl | Metformin Hcl | 243 | 65 |
| Omeprazole | Omeprazole | 224 | 81 |
| Tamsulosin Hcl | Tamsulosin Hcl | 201 | 66 |
| Diclofenac Sodium | Diclofenac Sodium | 179 | 56 |
| Hydrochlorothiazide | Hydrochlorothiazide | 165 | 46 |
| Gabapentin | Gabapentin | 150 | 47 |
| Simvastatin | Simvastatin | 145 | 39 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 137 | 44 |
| Lisinopril | Lisinopril | 133 | 43 |
| Baclofen | Baclofen | 130 | 64 |
| Metformin Hcl Er | Metformin Hcl | 117 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 110 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 109 | 33 |
| Ozempic | Semaglutide | 109 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 104 | 34 |
| Eliquis | Apixaban | 100 | 27 |
| Atenolol | Atenolol | 99 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 95 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 92 | 28 |
| Meloxicam | Meloxicam | 87 | 47 |
| Januvia | Sitagliptin Phosphate | 85 | 20 |
| Allopurinol | Allopurinol | 80 | 25 |
| Trazodone Hcl | Trazodone Hcl | 79 | 26 |
| Alendronate Sodium | Alendronate Sodium | 76 | 22 |
| Furosemide | Furosemide | 76 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 70 | 30 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 68 | 18 |
| Sertraline Hcl | Sertraline Hcl | 68 | 19 |
| Myrbetriq | Mirabegron | 67 | 16 |
| Famotidine | Famotidine | 66 | 26 |
| Ezetimibe | Ezetimibe | 62 | 25 |
| Enalapril Maleate | Enalapril Maleate | 60 | 19 |
| Glimepiride | Glimepiride | 58 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 56 | 19 |
| Xarelto | Rivaroxaban | 54 | 13 |
| Synthroid | Levothyroxine Sodium | 51 | 13 |
| Ibandronate Sodium | Ibandronate Sodium | 50 | 15 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 50 | 25 |
| Jardiance | Empagliflozin | 47 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 46 | 20 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 46 | 24 |
| Pregabalin | Pregabalin | 46 | suppressed |
| Lidocaine | Lidocaine | 45 | 24 |
| Vascepa | Icosapent Ethyl | 45 | 12 |
| Glipizide | Glipizide | 43 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 40 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 40 | 18 |
| Montelukast Sodium | Montelukast Sodium | 40 | 13 |
| Carvedilol | Carvedilol | 39 | 13 |
| Finasteride | Finasteride | 39 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 38 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 38 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 37 | 18 |
| Buspirone Hcl | Buspirone Hcl | 36 | 13 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 34 | 11 |
| Meclizine Hcl | Meclizine Hcl | 34 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 34 | suppressed |
| Ramipril | Ramipril | 34 | 11 |
| Clonidine Hcl | Clonidine Hcl | 33 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 33 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 33 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 32 | suppressed |
| Hydrocortisone | Hydrocortisone | 31 | 20 |
| Mometasone Furoate | Mometasone Furoate | 31 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 26 |
| Valsartan | Valsartan | 29 | 11 |
| Alprazolam | Alprazolam | 27 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | suppressed |
| Folic Acid | Folic Acid | 25 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 25 | 11 |
| Nitroglycerin | Nitroglycerin | 25 | 14 |
| Valacyclovir | Valacyclovir Hcl | 25 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Cilostazol | Cilostazol | 24 | suppressed |
| Clonazepam | Clonazepam | 24 | 17 |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 24 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 19 |
| Dexlansoprazole Dr | Dexlansoprazole | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 16 |
| Dapagliflozin | Dapagliflozin Propanediol | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Procto-Med Hc | Hydrocortisone | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Azithromycin | Azithromycin | 15 | 11 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Proctozone-Hc | Hydrocortisone | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 12 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $169.16 · 7 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, CAMZYOS, Cologuard Collection Kit, ELIQUIS, FARXIGA, VERQUVO | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error